CME LIVE OPEN ACCESS

Clinical and Medical Engineering Live

Review Article

ISSN: 2997-612X

Literature Review with Associated Case Study and Protocol for Bronchial Asthma in Integrative Approaches

Christina Rahm*, M.S., Ph.D., Ed.D.

USA

Corresponding Author: Christina Rahm, M.S., Ph.D., Ed.D. USA

Received: 2024 Oct 01 **Accepted:** 2024 Oct 28 **Published:** 2024 Nov 22

1. Introduction

Bronchial asthma is one of the most widespread chronic diseases, which frequently affect many people around the world. This study aims to give a full account of bronchial asthma by considering recent publication reviews, a well-documented case study, and an integrative approach in its methodology. The underlying causes of asthma and associated triggers and various degrees of severity are explored in the literature review. It further explains the common means of treatment, including bronchodilators and steroid inhalers. The case study that follows can be set against this review. A comprehensive treatment plan for a 35-year-old woman with asthma is discussed in detail as a case study. The plan consists of medications, a special formula for foods, and exercise that manages stress. One and two months after implementing this program, the patient exhibited a good improvement of the symptoms accompanied by better lung function results. Secondly, a literature review on the possibly therapeutic effects of herbal remedies such as nigella sativa and curcumin on asthma management is examined, taking into consideration animal and human studies. In addition, the integrative protocol suggested in our study outlines the need for extra measures like stress reduction and exercises. These blends are high in vitamins, minerals, and herb extracts that the protocol uses. In general, this study provides an area of contribution towards an integrated approach to asthma care, which is focused on patient-centeredness. An integrative approach using a combination of conventional drugs, special mixtures, and stress management techniques can be very useful in coping with bronchial asthma, as elucidated in the ISNS case study.

1.1 Literature Review on Bronchial Asthma

Bronchial asthma, which is a multi-factorial illness afflicting a large part of the world's population, is a result of the interaction between genetic and environmental factors. The research done by Figueiredo is pertinent to this study because it illustrates how complex bronchial asthma is, which is a widespread, difficult condition that affects many individuals on the planet [1]. Although this involves chronic inflammation that may be genetically predetermined, there is a strong association with environmental factors as well. Asthma is underpinned by a Th2-type immune response, being the central point through which inflammation, airway hyperreactivity, and remodeling occur [1]. This indicates that many cases present with the allergic phenotype, which accounts for why most forms are linked to immunologic aberration. Various types of effector cells, such as the lymphocytes and the eosinophils, work together by communicating through intracellular signaling pathways at some crucial point, which keeps the inflammation going. This study also reveals ongoing research works on ion channels as the primary source of inflammation during asthma. Exploitation of these areas provides additional therapeutic leads that can be used to target this complex airway pathology.

The crucial contribution of many ion channels to molecular responses involved in inflammation and bronchospasm is the basis for this intriguing, complex scenario of bronchial pathogenesis. The latter include transient receptor potential channels and store-operated Ca2+ channels, which have been identified as important players in this intricate sequence of events [1]. This complex dance includes the activation of Ca2+-activated K+ channels, which also modulate cell response. Further, there is a complex system that involves Calcium-activated Chloride channels, CFTR, and Piezo-type mechanosensitive ion channel component 1, which affects the pro-inflammatory state and airway responsiveness. This intricate pattern is made even more complex with the addition of purinergic P2X receptors, providing further proof that a wide number of molecular players are involved in the biochemistry of asthma. This not only improves understanding of the disease but also provides a possible direction for therapy targeting the disease-causing ion channels [1]. These channels emerging as possible pharmaceutical targets provide the expectation of newly developed drugs that can alter specified mechanisms involved in the aggravation and worsening of asthma, making treatment strategy more appropriate.

Asthma has a huge effect on global population health, affecting millions of people across different age groups and nationalities, as exemplified by Shinde [2]. Asthma occurs in different forms and is on the increase in both rich and poor countries. The challenge of managing asthma is

compounded by the fact there are not enough healthcare facilities as more people go undiagnosed, leading to suffering from asthma among affected communities. Pathophysiology of asthma involves multiple cells and signaling molecules like T-lymphocytes, B-lymphocytes, mast cells, eosinophils, dendritic cells, macrophages, and chemokines [2]. However, different cellular components participate in one way or another in the complex web of inflammatory reactions linked with asthma, and a variety of factors such as age and sex, among many other forms of exposure to the environment, can trigger these sure. This intricate understanding of asthma's pathophysiology involves developing specific treatment strategies that respond appropriately to various presentations of asthma in different communities.

Among Bush's points on holism about asthma, there is a critical emphasis on eroding the conventional notion that asthma is a global medical diagnosis [3]. However, this move involves going into more detail, focusing on distinct, treatable symptoms that are part of the overall picture. Such an approach requires detailed accountability for different parameters like fixed and variable airway obstruction, inflammation, infection, as well as abnormal cough reflex [3]. Clinicians can identify patients by their specific disease physiologies through this recognition and subsequently apply individual interventions for patients. Significantly, recognition includes recognizing other reversible characteristics like variable airflow obliteration that happens due to smooth muscle contraction, eosinophilic airway infections, and chronic bacterial infection. Specifically, Bush highlights that important characterizing features can be detected by noninvasive tests like spirometry, peripheral blood eosinophil count, induced sputum, and exhaled nitric oxide, which are indispensable in discerning these treatable [3]. The current model follows the emerging notion of precision medicine in asthma and highlights the need for personalized treatment depending on the individual asthma pathology.

King suggest that the use of advanced imaging approaches is central to comprehending the complexity of asthmatic pathways [4]. They stress a three-dimensional image of the lung disease that includes computerized tomography and ventilation imaging to emphasize its heterogeneous nature. Such refined technologies have taken measurements of traditional asthma beyond mere structural and ventilatory abnormalities. Specific imaging leads to refined data about pathophysiological actions taking place in the lungs [4]. Consequently, it is possible to comprehend different types of asthma by having the ability to explain their intensity, which is dependent on the level of airflow narrowness. This is why adding advanced imaging helps us understand how complex asthma can be but, most importantly, helps us formulate personalized treatment approaches. These imaging technologies allow one to visualize the subtle complexities involved with lung function and structure and hence provide a basis for designing customized interventions designed to match the peculiar aspects of the particular individual's type of asthma.

In addition, the Paudel study discusses the worldwide effects of bronchial asthma and explores such challenges using a case study set in a village in a hilly environment in Nepal [5]. This study sheds light on the significant issues associated with asthma that go beyond mere physical aspects.

From a multidimensional perspective, asthma is the main underlying problem leading to various complications such as the deterioration of health conditions, limited ability to be involved in social life, and difficulties with daily activities. Such a mountainous background provides distinct difficulties as far as asthma management is concerned in an even more complex environment [5]. Asthma patients in this environment are burdened with additional challenges, including inadequate health facilities and poor living standards. The results, therefore, underscore the importance of exploring issues of region/environmental relatedness when it comes to understanding the complexities of asthma origin and, finally, intervention to fit the localized problems of asthma occurrence.

A major step towards understanding asthma has been marked by the comprehensive review by Habib, Pasha, and Tang on the molecular mechanisms involved in the initiation and persistence of asthma [6]. It is also worth noting that the shift towards genotyping and identifying Th2-high and Th2-low asthma speaks to the intrinsic heterogeneity of asthma itself. The identification of Th2 inflammation as a key component has informed this departure from traditional extrinsic and intrinsic asthma classification [6,7]. The investigation of new therapeutic paths, such as monoclonal antibodies, heralds the dawn of the age of more precise and successful therapy personalized to each subtype. In particular, the discovery of useful clinical markers of Th2-predominant asthma, such as eosinophils, IgE, fractional exhaled nitric oxide, and periostin, helps to characterize this type of asthma. This is an important process that will help in defining complicated forms of endotypes and identifying useful biomarkers for precise asthma diagnostics and treatments, eventually leading to individual oriented patient care strategies.

Asthma is among the leading respiratory diseases that affect many children residing in rural areas and cities with poverty levels. This is one of the most widespread types of respiratory disease, which causes serious health problems all over the world. On the other hand, asthma presents itself as being complicated because of multiple underlying causes that combine genetics, the environment, and behavioral factors. Asthma is hereditary, and individuals are more susceptible as a result of their family lineage. Also, environmental factors that include exposure to allergens, pollution, and respiratory infections stimulate or aggravate asthma.

Additionally, lifestyle factors such as physical inactivity and obesity make the condition worse. It is important to understand these connected components to develop efficient prevention and management strategies. As such, the children living within marginalized communities are more vulnerable. The complexity of asthma determinants

requires the adoption of comprehensive strategies that are centered on improving child respiratory health outcomes and guaranteeing universal health coverage.

Elaboratively, a family history of asthma proves a strong and established risk for the development of asthma in children. Oland, Booster, and Bender confirm this significant family link, stating that persons who had an affected parent are three to six times more likely to be vulnerable to asthma [8]. The above genetic predisposition emphasizes how crucial a child's family background is to their asthma risks or vulnerability. The ability of familial influences on the development of asthma becomes essential in assessing a child's risk and developing interventions for such children. Kuruvilla further elaborate on this knowledge by pointing out the vast similarity of the underlying risk factors of childhood and adult asthma [9]. Genetic interactions over many generations emphasize that there should be multigenerational family study of asthma as it requires a full understanding of its origin and ways of prevention.

Recent work by Kyvsgaard and his colleagues reveals early-life experience, including breathing difficulties in childhood, as one of the most important risk factors for asthma [10]. The study shows that premature birth, cesarean section as well as lowered birth weights lead to a high likelihood of developing asthma-like symptoms by age five [10]. These symptoms demonstrate the continued effects of respiratory challenges during infancy on the programming of the lungs and the respiratory system. This conforms with the general notion that the early-life environment and related exposure determine the health of the airways at the adulthood stage. These results point to the critical role of early life in the prevention and control of asthma through tailored interventions and comprehensive treatment schemes that aim at minimizing lifetime lung diseases.

Asthma exacerbations can be triggered by exposure to allergens, which was highlighted by several research papers, including that of Woolhouse. A recent Lancet Regional Health-Western Pacific study carried out by Edelwina and colleagues recognizes that exposure to airborne allergens plays a significant role in causing asthma while at the same time acknowledging that tobacco smoke plays a notable role in predisposing to asthma [11]. It points to the necessity of going beyond the usual environmental triggers and including others like tobacco smoke in consideration. More importantly, Kuruvilla highlight the well-known association between sensitization to inhalant allergens and asthma occurrence, noting a significant increase in asthma risk following allergen sensitization during early life [9]. It becomes necessary to identify, prevent, or control indoor allergens that lead to an asthmatic condition.

This shows that early interventions are very important, especially during the infant stage, where there is minimal risk for asthma due to exposure to allergens. Together, these studies show that there is a complex link between allergic exposures and asthma, suggesting the need for strategic interventionist policies and measures. The role of the environment, especially smoking and air pollution, in causing asthma has been proven in many studies, such as the study done by Edelwina and Kuruvilla [9,11]. Although Philippine laws prohibit smoking among children, there is still a large number of Filipino children who are exposed to cigarette smoke, thus showing that it is difficult to enforce regulation and control environmental exposure [11]. This underlines the need for stronger regulation as well as potent public health programs that seek to protect the young generation against tobacco smoke. Kuruvilla also highlight the role that indoor allergens such as tobacco smoke may have in increasing the risk for asthma and, hence, justification for the adoption of intervention strategies [9]. It is important to address environmental triggers to manage asthma exacerbations and improve respiratory well-being. These two studies highlight the ongoing struggles of limiting smoking exposures, advocating for healthier environments for kids, and alleviating environmental risk factors for childhood asthma.

Healthy people in low-income groups suffer from the disease and contribute to health inequalities within such communities. As observed by Oland asthma is a disease that hits poor and minority kids living around the cities quite hard as compared to other people outside or even elsewhere, like in another city [8]. By giving an example of the experience of a student in the Philippines in the studies done by Edelwina the study conducted in the Western Pacific region brings clarity to this understanding [11]. They meet problems of equal access to health education and exacerbate the difficulties of people living in low-income families because, despite existing legal norms restricting tobacco use among children, there are serious deficiencies in education programs aimed at smoking prevention. This evidence supports that the relationship between socio-economics and health outcomes are complex, hence necessitating target-specific policies to mitigate asthma health inequalities underpinning socioeconomic indicators.

The findings of research done by Oland and Kuruvilla have indicated that psychological and lifestyle factors are important causal factors for asthma exacerbations [8,9]. Asthma gets worsened by chronic stress and problems with children's psychology as well as family behavior. This points to the synergy between physical and mental wellness. Similarly, Kuruvilla highlight psychological factors, including maternal asthma, prebirth smoking, and allergic sensitization in childhood asthma [9]. The research highlights that any effective medical program designed for the prevention and management of asthma must focus on the socio-emotional aspects of illnesses, including mental health. Asthma is a chronic condition that makes people prone to mental distress; hence, introducing preventive strategies will benefit the victims of this disease by improving their mental health and well-being in general.

Lifestyle factors such as obesity and physical inactivity have been indicated as risk factors that can contribute to asthma development and aggravation. Oland highlight the link between overweight and a higher likelihood of

asthma development, pointing to systemic inflammation, which could influence respiratory functions [8]. This goes along with the work done by Kyvsgaard who investigated the complex association between lifestyle decisions and early life events on asthma risk [10]. For instance, this study by Kyvsgaard and his colleagues shows that extreme prematureness combined with low birth weight increases prescriptions of asthma medication among preterm newborns. These parallel observations illustrate the complex nature of asthma risk factors that include personal lifestyle decisions as well as early life exposures. This emphasizes why one should consider present behaviors as well as earlier components in determining asthma risk. This information is very useful in developing preventive efforts that are tailored to an individual's unique needs in managing asthma.

Asthma, a chronic inflammatory disorder affecting the lungs, is characterized by variable symptoms requiring classification systems based on frequency of occurrence and severity. However, in its categorization, the global initiative for asthma guidelines using the different parameters for the assessment of its severity is very important. Some of these parameters include PRESS, Pediatric Asthma Symptom Scale, and PRAM [12]. It is important to keep in mind that the severity of asthma is one of several factors that will inform the most appropriate management for an individual. PRESS is a tool that assesses specific respiratory parameters and classifies the severity of disease as mild, moderate, or severe, depending upon the summation. In addition, the Pediatric Asthma Symptom Scale measures the number and seriousness of episodes to produce a complete evaluation instrument [12]. Also, PRAM is a 12-point clinical scoring system that helps assess the severity of asthma attacks and adds more insight into the burden of the disease for patients. In brief, these classification tools play an important role in assisting doctors with individualized disease management as they help select the best therapy for various patients' severity of the disease.

Useful criteria for measuring asthma severity in children are presented by Ali [12]. PRESS becomes an all-inclusive scoring system that takes into consideration features like tachypnea, wheezing, retractions, oxygen saturation, and feeding problems. Scoring between 0 and 1 is considered mild while scoring between 2 and 3 is moderate; moreover, scoring between 4 and 5 is severe, providing an opportunity to understand how each symptom affects the patient's overall health condition. Furthermore, the Pediatric Asthma Symptom Scale also gives a broader picture of how often and how severe symptoms occur. Scores are higher as the symptoms become more intense and often occur. These allow physicians to formulate interventions depending on an individual's situation and requirements.

Furthermore, the PRAM, which is a twelve-point clinical scoring method, is also important in assessing the worsening of asthma [12]. The classifications of mild (0–3), moderate (4–7) and severe (8–12) enable a systemic recognition of exacerbation degrees that is generally accepted, enabling clinical decisions and planning of interventions. In summation, the use of these tools together increases the accuracy of measuring asthma in children for better care. Garcia-Marcos global cross-sectional study investigates the complex relationship between asthma symptom experience and asthma medication use [13]. This provides important evidence for the management and control of asthma. This study closely scrutinizes the usage pattern of medications based on the intensity of asthma symptoms and explores possible connections between the degree of symptoms and drug treatment.

The findings underscore a notable correlation: with an increased intensity of asthma symptoms, there is a corresponding increase in inhaled as well as oral asthmatic drug use. Such an observed pattern gives rise to interesting queries concerning the causality between the symptoms' severity and the drug [13]. The focus on comorbidity in this paper underscores the difficulties involved in managing asthma symptoms and using medication simultaneously. Through this critical examination, the contribution of scientific understanding regarding asthmatic patients' different degrees of symptom severity is made with regard to the implementation of focused and efficient treatments.

Moreover, García-Marcos in their study, highlight the broad application of Oral SABA and theophylline, which are less productive and have more side effects than inhalation therapy [13]. The use of oral SABA, especially by people experiencing severe asthmatic symptoms, challenged traditional guidelines for asthma action plans, raising concern about poor symptom control following this new paradigm. Even though theophylline is not recommended, it was commonly used, particularly in less developed countries, which may suggest some barriers to inhaled drugs [13]. It further highlights inequity in ICS utilization among upper-middle-income and low-income economies. These raise questions about the availability and affordability of the necessary asthma medicines and underscore the need for specific measures to tackle these gaps.

The article by Tilahun and Eyasu provides an excellent analysis of past data for determining the level of severity of asthma among adult patients [14]. Importantly, these results suggest that the moderate nature of asthma is common amongst the majority of patients, stressing the significance of recognizing the varying levels of asthma severity within this population. It stresses the correct diagnosis of asthma severity, which plays a critical role in optimal medical treatment. It provides detailed information about the various contributing factors, such as gender, occupation, and smoking, to enhance the analysis of how these conditions are associated with moderate asthma. These insights help design culturally appropriate interventions and individualized treatments for the diversity of socio-demographic settings prevalent among Ethiopia patients with worse forms of asthma [14]. Since it explores the peculiarities of asthmatic states in this part of Asia, its results are relevant to the global discussion about effective management programs and highlight the context approach in healthcare decision-making.

Traditionally, asthma management has entailed the use of bronchodilators and corticosteroids through inhalation, forming the basis of treatment [15,16]. Bronchodilators like beta agonists relax constricted airway muscles and provide relief for acute exacerbation. On the contrary, steroids, especially ICS, target the chronic inflammation aspect of asthma, hoping to lower the frequency of attacks and avoid permanent damage to the lungs. The traditional way is now widely accepted as a method proven by organizations such as the Global Initiative for Asthma (GINA) through numerous years of practice.

Research has unveiled transformations in the treatment of asthma, where GINA has come up with new guidelines [15,16]. There is increased research on patients' attitudes towards changes in treatments, and it has discovered the importance of factors, like perceived effectiveness of the new treatment techniques, doctor's advice, and patient knowledge in influencing consideration of various treatment options. Transitioning into new therapies in asthma care requires understanding patients' views and ideas to prevent the process from failing.

The latest guidelines from GINA for 2022 emphasize that primary care is critical when developing a plan for treating asthma [16]. The guidelines stress upon reconfirmation of diagnosis by spirometry or peak flows and specifically identifiable treatment regimes in asthma patients. Most asthma patients should be prescribed inhaled corticosteroids (ICS) as a measure of preventing severe exacerbations, even though it should be done with the understanding that treatment is a case-specific matter [16]. Despite these guidelines, papers such as Davitte highlight difficulties in managing controlled asthma at various GINA stages, stressing the symptomatic burden on affected individuals while they receive treatment for asthma in outpatient clinic care [17].

Asthma treatment is advancing in highly developed countries, while Barne indicates that there exist many disparities in asthma diagnosis and management in LMICs [18]. Asthma is a major contributor to global asthma morbidity and mortality in LMIC but also faces significant challenges such as poor infrastructure, lack of access to care, and high cost of drugs in the region. These barriers comprise the absence of health policies, deficient healthcare infrastructure, and scant knowledge and expertise amongst providers in early diagnosis and appropriate management [18]. The social and systemic differences between LMICs have been a major issue in improving the quality of life for people with asthma to an almost normal range.

1.2 Case Study on Bronchial Asthma

A 35-year-old female patient with a family history of and having repeated symptomatic signs of bronchial asthma is involved in this case study. She presents with acute episodes of wheezing with chest tightness, cough and dyspnea mostly due to environmental triggers (e.g., exposures) and exercise. Six months ago, after a careful assessment, it was revealed that the patient had asthma. Initial clinical tests, especially the Tiffeneau index of VC/FEV1/VC, which is 75 %, revealed impairment of airways' function [19]. The data provide a complete description of the patient's demographic profile, his symptomatic profile over previous months, the most recent asthma diagnosis, and the baseline pulmonary function testing result as a basis for extensive diagnostics and multimodality therapeutic algorithm development.

Regimens for the treatment of Bronchial Asthma include medicine mixes, proprietary blends, and further medical procedures. Rescue medication comprises montelukast inhalers containing montelukast, formoterol, beclomethasone, and ipratropium-fenoterol, among others. These inhalers are important in symptom control by targeting airway inflammation and bronchoconstriction [19]. Simultaneously, the patient is administered six particular formulations that are made up of unique amounts and frequencies of vitamins, minerals, and herbal extracts. Such blends form a complementary whole, enhancing traditional medicines with nutritional and herbal support. There is also, the incorporation of stress management exercises, yoga, meditation as well as breathing exercises in the comprehensive management that focuses on the psychological aspect of bronchial asthma. The multimodal approach seeks to relieve acute symptoms and improve the general well-being of patients living with this chronic respiratory disorder.

Throughout the two months of integrative treatment for bronchial asthma, there were signs of improvement in the patient. Just after one month, there were significant reductions in the severity of asthma symptoms like coughing, wheezing, chest tightness, and shortness of breath. A significant reduction of acute attacks' frequencies, which amounted to 7 in a week, demonstrated a positive initial result from combined therapy [19]. However, during the second month of the treatment, the patient recovered substantially with no acute attacks at all. However, this remarkable result was also accompanied by significant improvement in the Tiffeneux index, which started at 75% and grew up to 89%. These results highlight the possibility that an integrative protocol involving prescription medications, proprietary blends, and other interventions, such as stress management/exercise, could result in a comprehensive and sustained improvement in asthma outcomes.

1.3 Medicinal Agents for Bronchial Asthma Management

Black seed or black cumin with an alias name of Nigella sativa (NS) has been considered with many prospects for treatment in asthma. He Xu's systematic review and metaanalysis examined the effect of Nigella sativa on asthma control [20]. Four RCTs were involved in the meta-analysis, which indicated that asthma control score, FEV1 as an indicator of improved lung functions, as well as PEF, IL-4, and IFN-γ, did not reveal any significant changes. Thus, NS could serve as a complementary remedy to asthma therapy with regard to symptom alleviation and increased pulmonary function.

In addition, research by Ikhsan focused on the anti-inflammatory effects of N. sativa. The lab experiment was

performed using Wistar's peritoneal mast cell stimulation with C 48/80 released histamine [21]. Ethanol extracts of different concentrations were given, including 0.1 mg/ml to 0.5 mg/ml. Results showed that N. sativa had anti-inflammatory effects on mast cells in a dose-dependent manner. The more concentrated the N. sativa, the lesser the amount of histamine released, which could be attributed to its anti-inflammation properties.

Curcumin, a natural phytochemical substance obtained from turmeric, is interesting because it possesses a multitude of antioxidants and anti-inflammatory agents. The clinical effectiveness of chronic asthma has, however, been compromised due to poor aqueous solubility, fast metabolism, and short half-life. These shortcomings are addressed by Chawla in their study of an intranasal delivery system that includes curcumin-loaded micellar suspension for treating persistent asthma [22]. MPEG5000-DSPE micellar dispersion had good attributes like mean particle sizes in the range from twenty to about twenty-six and with the negative Zp value. Importantly, adding curcumin in micelles enhanced its solubility and prevented its oxidation. Using an ovalbumin-induced allergic asthma model in male rats, Wistar showed fourteen times upscale in the bioavailability of curcumin and a fourfold higher concentration of the drug in the lungs at the micellar way. Curcumin micelle offers a protracted release profile over about 36 hours, and significant suppression of ROS within asthmatic cells suggests their utility for asthmatic management.

Quan as cited by O'Loughlin also conducted a randomized, placebocontrolled, double-masked pilot trial to contribute to this exploration [23]. This is a special study that involves an assessment of the use of curcumin as an adjunct therapy among moderate to severe asthmatics. The use of curcumin is based on two hundred years of precedent in Eastern medicine as an anti-inflammatory agent; it has proved effective in mice, leading to decreased levels of inflammatory markers and enzymes such as IL-6R. The main goal of this trial is to narrow down the difference between using Eastern herbs and Western medicine in order to study if curcumin can be used together with lung diseases such as asthma at no cost or low cost. Findings from this trial could help uncover better strategies for managing patients with moderate to severe asthma that are inexpensive and simple to access. Furthermore, it offers scope for the inclusion of curcumin into regular asthma protocols.

1.4 Protocol for Integrative Approach

Silica, Vitamin C, and trace minerals make up Blend I, which works in synchrony to combat critical elements of lung and general wellness. It is also well known that silica, a natural compound, supports connective tissues like those of the respiratory system. It helps to preserve some level of structural integrity of the lung tissues that may assist in achieving normal respiratory functions. Vitamin C is an important antioxidant that combats a major cause of most respiratory complications, such as asthma, known as oxidative stress. Vitamin C is also known for boosting immunity and may, hence, be helpful in controlling exacerbations due to infection [24]. The addition of trace nutrients also improves the mixture through the provision of dietary micro-nutrients that assist a number of physical functions, which help increase the overall resistance of the respiratory as well as immune systems. These constituents in Blend I contribute to an integral outlook for a healthy breathing system as part of whole-body health.

Blend II is a unique synergistic blend of several compounds targeting different aspects of Bronchial Asthma management. N-acetyl L-tyrosine (an amino acid derivative) might help people with asthma cope up with the psychological aspects as it could be important for their cognitive function and stress reduction. One common bronchodilator used in treating asthma is caffeine. This drug can also serve to improve the effectiveness of other drugs for asthma as well as reduce the incidence of asthmatic symptoms. This is because L-theanine, which is an amino acid derived from tea leaves, contains a calming effect that can neutralize the stimulant effects of caffeine, making people alert but concentrated. Velvet Bean Seed can reduce airway inflammation in asthma due to its potential anti-oxidants and anti-inflammatory agents. Pine Bark, an anti-inflammation substance that also helps modulate the immune system, enhances the overall plan against inflammation [25]. In addition to it, there is curcumin, which has proved to be anti-inflammatory, and vitamin D, which is important for the immune system related to asthma. These are some parts that makeup Blend II, where multiple ways are provided that would help the patient's physical and mental aspects.

Blend III is a mixture of Black Seed Oil, Resveratrol, Turmeric, Raspberry Ketone, Apple cider vinegar, Aloe Vera, and D ribose; these are natural components that can act as boosters in your body—combining black seed oil (anti-inflammatory and immune modulator) with resveratrol (red grape-derived antioxidants). Besides, this one is usually combined with traditional medication due to its anti-inflammatory and anti-oxidative effects. This is because of Raspberry Ketone that comes from red raspberries and allegedly aids in maintaining the body's metabolism rate [26]. The use of apple cider vinegar is known to have a positive effect on digestion as well as metabolism. The application of aloe may also be helpful. Lastly, D-ribose, a natural sugar that contributes to energy metabolism, constitutes the final part of the blend [27]. Taken together, these constituents constitute a myriad of ways through which Blend III may promote health.

Blend IV, which includes Vitamin C, Zinc Sulfate, and Vitamin D3, represents a blend of vital micronutrients required for health and immune function. One of the most important immunity-supportive roles is provided by vitamin C, which is also a powerful antioxidant. Trace element zinc could not possibly be dispensed with in the normal evolution and operation of immunocytes. It is an important factor in respiratory health because of its immune response modulation and anti-inflammatory properties. The so-called Sunshine Vitamin, Vitamin D3, is important for the regulation of the immune system and tends to diminish respiratory infections [28]. These four components make

blend IV able to achieve a balanced reaction and, therefore, can be used in managing bronchial asthma. A combination of these micronutrients not only compensates for the existing weaknesses but also meets the modern view of the relation between nutrition and immunity, thereby providing a complete scheme to assist asthmatic patients' respiratory systems.

The blend V, which consists of fibers, probiotics, and other highly nutrition-yielding foods, is an essential part of the integrative procedure for the treatment of bronchial asthma. Fiber is important for the proper functioning of bowels and for maintaining healthy bacteria in your intestines. The concept of the gut-lung axis is highly relevant to asthma management, where communication between the gut and lung is complex. Because probiotics are good at influencing gut flora, they can affect systemic inflammation, which may ultimately help with asthma symptoms [29]. This ensures a broad range of nutritious foods, providing a full complement of vitamins, minerals, and antioxidants that are vital for good fitness. It is based on the recognition that if the body has nutrients, it is easier for it to fight the inflammation component of asthma; therefore, this is holistic. Blend V addresses the gut-lung axis and promotes systemic health as it reflects an integrative approach to treating bronchial asthma, which recognizes a complex interplay between different body systems.

Blend VI is a complex blend of essential components that take a holistic approach in regard to respiratory health at large, as well as specific issues associated with bronchial asthma itself. Considering that the inclusion contains nicotinamide adenine dinucleotide (NAD+), which is a coenzyme important in producing the cellular energy of respiratory cell functions, it could aid in managing asthmatic symptoms. Magnesium, which has been proven to be a bronchodilator, helps relax the muscles of the airways, hence making breathing easier. As such, adding trace minerals helps create a complete mineral profile that may boost several physiological functions. Flavonoids such as quercetin reduce inflammation in the airways, which is one of the main causes of the development of asthma pathogenesis. Vitamins D, C, and K2, which have functions related to immune modulation that can improve the body's defensive mechanism and possibly respiratory state, are also blended [24]. It is this rich mix that illustrates the whole approach to breathing in order of those who have bronchial asthma.

The blend of seven of the suggested protocols for the treatment of bronchial asthma combines hydrolyzed bovine collagen powder and whole bovine colostrum powder. Hydrolyzed Bovine collagen is produced from cattle, where it undergoes a hydrolysis process to produce small digestible peptides. Collagen constitutes connective tissues, skin, and bones with the assumption that it plays a role in tissue repair and whole-body architecture. Collagen supplementation can be useful for asthma since it may promote the repairing of damaged airways. At the same time, the Whole Bovine Colostrum Powder is a rich nutritional liquid secreted by cows within early days postpartum. Colostrum is associated with proteins (antibodies), growth factors, and nutrients that are important for the development of immunity and general wellness [30,31]. The addition of these ingredients into Blend VII points to a desire for a broader scope of asthma treatment that also takes into account respiratory tissue as well as general immunity. However, research still needs to establish the exact positive impact of this particular nutrient on bronchial asthma [32].

2. Conclusion

The case study, as well as the literature review outlining the integrative strategy, suggest a new context in the management of bronchial asthma with an expectation of better patient success. A combination of conventional pharmaceutical interjections in unison with complementary therapies that include proprietary blends, NS, and curcumins leads to this all-in-one solution for an asthmatic treatment regime. Such a subtle approach highlights both the significance of this relationship between genetic and environmental elements and the necessity for personalized therapy to ensure an effective response. Therefore, the proposed protocol, which contains the predesigned proprietary combinations directed specifically towards different facets of asthma pathogenesis, is a beneficial guideline for healthcare providers. To this end, it fosters an individualism-based mentality, which acknowledges the multi-faceted elements of leukemia as well as the different requirements of every patient. Practitioners may help develop a paradigm shift in asthma management where patients aim at long-term well-being rather than just controlling symptoms, leading to improved quality of life among patients.

References

1. Figueiredo, I. A. D., Ferreira, S. R. D., Fernandes, J. M., Silva, B. A. D., Vasconcelos, L. H. C., et al (2023). A review of the pathophysiology and the role of ion channels on bronchial asthma. *Frontiers in Pharmacology*, 14, 1236550.
2. Shinde, V., Wankhede, P., Vyawahare, N. (2023). Asthma: cells involved in the pathophysiology of asthma. The *Journal of Association of Chest Physicians, 11*(1), 10-18.
3. Bush, A. (2019). Pathophysiological mechanisms of asthma. *Frontiers in pediatrics*, 7, 68.
4. King, G. G., Farrow, C. E., Chapman, D. G. (2019). Dismantling the pathophysiology of asthma using imaging. *European Respiratory Review, 28*(152).
5. Paudel, S., Shankar, P. R., Subedi, N., Palaian, S. (2023). Living with bronchial asthma: A qualitative study among patients in a hill village in Nepal. *Plos one, 18*(10), e0291265.
6. Habib, N., Pasha, M. A., Tang, D. D. (2022). Current understanding of asthma pathogenesis and biomarkers. *Cells, 11*(17), 2764.
7. Suraya, R., Nagano, T., Katsurada, M., Sekiya, R., Kobayashi, K., et al (2021). Molecular mechanism of asthma and its novel molecular target therapeutic agent. *Respiratory Investigation, 59*(3), 291-301.
8. Oland, A. A., Booster, G. D., Bender, B. G. (2017). Psychological and lifestyle risk factors for asthma exacerbations and morbidity in children. *World Allergy*

Organization Journal, *10*, 1-7.
9. Kuruvilla, M. E., Vanijcharoenkarn, K., Shih, J. A., Lee, F. E. H. (2019). Epidemiology and risk factors for asthma. *Respiratory medicine, 149*, 16-22.
10. Kyvsgaard, J. N., Chawes, B. L., Horner, D. L. G., Hesselberg, L. M., Melgaard, M. E., et al (2023). Risk factors and age-related patterns of asthma-like symptoms in early childhood. *The Journal of Allergy and Clinical Immunology: In Practice, 11*(6), 1773-1784.
11. Legaspi, K. E. Y., Dychiao, R. G. K., Dee, E. C., Kho-Dychiao, R. M., Ho, F. D. V.et al (2023). Pediatric asthma in the Philippines: risk factors, barriers, and steps forward across the child's life stages. *The Lancet Regional Health–Western Pacific*, 35.
12. Ali, H. A. (2023). Quality of life and its relation to pediatric asthma severity. *The Egyptian Journal of Bronchology, 17*(1), 47.
13. García-Marcos, L., Chiang, C. Y., Asher, M. I., Marks, G. B., El Sony, A., et al (2023). Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study. *The Lancet Global Health, 11*(2), e218-e228.
14. Tilahun, D., Michael, M., Gashaye, M., Melkamu, E., Mekoya, T. et al (2022). Retrospective cross-sectional study of asthma severity in adult patients at the Jimma Medical Center, Ethiopia. *Scientific Reports, 12*(1), 11483.
15. Holst, S. S., Sabedin, E., Sabedin, E., Vermehren, C. (2023). A shift in asthma treatment according to new guidelines: an evaluation of asthma patients' attitudes towards treatment change. *International Journal of Environmental Research and Public Health, 20*(4), 3453.
16. Levy, M. L., Bacharier, L. B., Bateman, E., Boulet, L. P., Brightling, C., et al (2023). Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. *NPJ primary care respiratory medicine, 33*(1), 1-13.
17. Davitte, J., DeBarmore, B., Hinds, D., Zhang, S., Chao, J., et al (2023). Asthma control among treated US asthma patients in Practice Fusion's electronic medical record research database. *NPJ Primary Care Respiratory Medicine, 33*(1), 17.
18. Barne, M. (2023). Gaps in asthma diagnosis and treatment in low-and middle-income countries. *Frontiers in Allergy, 4*, 1240259.
19. Ketskés, N., Rahm, C. Bronchial Asthma.
20. He, T., Xu, X. (2020). The influence of Nigella sativa for asthma control: A meta-analysis. *The American journal of emergency medicine, 38*(3), 589-593.
21. Ikhsan, M., Hiedayati, N., Maeyama, K., Nurwidya, F. (2018). Nigella sativa as an anti-inflammatory agent in asthma. *BMC research notes, 11*, 1-5.
22. Chawla, R., Sahu, B., Mishra, M., Rani, V., Singh, R. et al (2022). Intranasal micellar curcumin for the treatment of chronic asthma. *Journal of Drug Delivery Science and Technology, 67*, 102922.
23. Quan, M., Alismail, A., Daher, N., Cleland, D., Chavan, S., et al (2021). Randomized, placebo controlled, double blinded pilot superiority phase 2 trial to evaluate the effect of curcumin in moderate to severe asthmatics. **BMC Pulmonary Medicine, 21**, 1-8.
24. Zajac, D., Wojciechowski, P. (2023). The Role of Vitamins in the Pathogenesis of Asthma. *International Journal of Molecular Sciences, 24*(10), 8574.
25. Verlaet, A., van der Bolt, N., Meijer, B., Breynaert, A., Naessens, T., et al (2019). Toll-like receptor-dependent immunomodulatory activity of pycnogenol®. *Nutrients, 11*(2), 214.
26. Rao, S., Kurakula, M., Mamidipalli, N., Tiyyagura, P., Patel, B., et al (2021). Pharmacological exploration of phenolic compound: raspberry ketone—update 2020. *Plants, 10*(7), 1323.
27. Chen, Y., Yu, L., Wang, Y., Wei, Y., Xu, Y., et al (2019). d-Ribose contributes to the glycation of serum protein. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1865*(9), 2285-2292.
28. Marusca, L. M., Reddy, G., Blaj, M., Prathipati, R., Rosca, O., et al (2023). The effects of vitamin D supplementation on respiratory infections in children under 6 years old: a systematic review. *Diseases, 11*(3), 104.
29. Ciprandi, G., Tosca, M. A., Drago, L. (2023). Probiotics in asthma management: fiction or truth? *Expert Review of Clinical Immunology, 19*(5), 457-460.
30. Ooi, T. C., Ahmad, A., Rajab, N. F., Sharif, R. (2023). The effects of 12 weeks colostrum milk supplementation on the expression levels of pro-inflammatory mediators and metabolic changes among older adults: findings from the biomarkers and untargeted metabolomic analysis. *Nutrients, 15*(14), 3184.
31. Kim, K., Lee, J. Y., Kim, Y. M., Kim, G., Kim, E. H., et al (2023). Prevalence of asthma in preterm and associated risk factors based on prescription data from the Korean National Health Insurance database. *Scientific Reports, 13*(1), 4484.
32. Moore, L. E., Serrano-Lomelin, J., Rosychuk, R. J., Kozyrskyj, A. L., Chari, R., et al (2023). Perinatal and early life factors and asthma control among preschoolers: a population-based retrospective cohort study. *BMJ Open Respiratory Research, 10*(1), e001928.